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FNDC5 expression and circulating 
irisin levels are modified by diet 
and hormonal conditions in 
hypothalamus, adipose tissue and 
muscle
B. M. Varela-Rodríguez1,2, L. Pena-Bello1,2,3, P. Juiz-Valiña1,2, B. Vidal-Bretal1, F. Cordido1,2,3 & 
S. Sangiao-Alvarellos1,2
Irisin is processed from fibronectin type III domain-containing protein 5 (FNDC5). However, a 
controversy exists concerning irisin origin, regulation and function. To elucidate the relationship 
between serum irisin and FNDC5 mRNA expression levels, we evaluated plasma irisin levels and FNDC5 
gene expression in the hypothalamus, gastrocnemius muscle and different depots of adipose tissue 
in models of altered metabolism. In normal rats, blood irisin levels diminished after 48-h fast and 
with leptin, insulin and alloxan treatments, and serum irisin concentrations increased in diabetic rats 
after insulin treatment and acute treatments of irisin increased blood insulin levels. No changes were 
observed during long-term experiments with different diets. We suggested that levels of circulating 
irisin are the result of the sum of the irisin produced by different depots of adipose tissue and skeletal 
muscle. This study shows for the first time that there are differences in FNDC5 expression depending 
on white adipose tissue depots. Moreover, a considerable decrease in visceral and epididymal adipose 
tissue depots correlated with increased FNDC5 mRNA expression levels, probably in an attempt to 
compensate the decrease that occurs in their mass. Hypothalamic FNDC5 expression did not change for 
any of the tested diets but increased with leptin, insulin and metformin treatments suggesting that the 
regulation of central and peripheral FNDC5/irisin expression and functions are different.
Metabolic syndrome is characterized by a series of disorders such as, obesity, insulin resistance, glucose intoler-
ance and hyperlipidemia. Obesity is a driver of metabolic syndrome and has emerged as one of the most impor-
tant medical problems of the 21st century that is a major risk factor for the development of cardiovascular diseases 
and type 2 diabetes (T2D). According to a World Health Organization estimate, diabetes mellitus affects 346 
million people worldwide1 and its prevalence continues to increase due to advancing age, increasing obesity rates 
and inactivity2,3.
Obesity is a very complex phenomenon in which plays very important roles peripheral tissues such as adi-
pose tissue, liver and muscle as well the neurohormonal and neurotransmitter dysregulation4–8. In this regard, 
the hypothalamus plays a key role in energy homeostasis. It controls food intake and senses multiple circulating 
peripheral signals such as leptin, insulin, adiponectin, gut hormones and nutrients that function as “indicators” 
that interact with specific hypothalamic regions to disturb the energy balance both peripherally and centrally9–11.
In 2012, Boström and colleagues discovered that in muscle, exercise increases the expression of FNDC5 
(Fibronectin type III domain-containing protein 5), a membrane protein encoded by the FNDC5 gene. The 
FNDC5 protein is cleaved and secreted as a new hormone called irisin12, suggesting that some of beneficial effects 
of exercise could be mediated by this hormone. Irisin induces the browning of white adipose tissue (WAT), 
thereby increasing thermogenesis and possibly improving glucose homeostasis12–14. There have been many studies 
1Department of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain. 2Instituto 
de Investigación Biomédica de A Coruña (INIBIC), Xubias de Arriba, 84. 15006, A Coruña, Spain. 3Division of 
endocrinology, Complexo Hospitalario Universitario de A Coruña (CHUAC), 15006 A Coruña, Spain. Correspondence 
and requests for materials should be addressed to S.S.-A. (email: susana.sangiao@udc.gal)
received: 16 April 2016
accepted: 22 June 2016
Published: 19 July 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:29898 | DOI: 10.1038/srep29898
attempting to correlate plasma irisin levels with metabolic disorders such as obesity, diabetes, non-alcoholic fatty 
liver disease (NAFLD) and polycystic ovary syndrome (PCOS) (both associated with metabolic syndrome), how-
ever, the results were not consistent among the various studies (reviewed by15). Recently, it has been reported that 
irisin is also produced by adipocytes14,16 and that it is present in human cerebrospinal fluid (CSF), although its role 
in the brain is largely unknown. FNDC5 inhibition reduces neurogenesis17, while its overexpression stimulates 
neural differentiation18, and pharmacological doses of irisin increase the proliferation of mouse hippocampal 
neuronal cells19 similar to the effects of endurance exercise, a process associated with the increased expression of 
brain derived neurotrophic factor (BDNF)20. In the hypothalamus, irisin appears colocalized with neuropeptide 
Y (NPY) in the neuronal cells of the paraventricular nucleus21. These findings support the idea that irisin has both 
peripheral and central functions. Despite the promising results, many aspects of the regulation, secretion and 
physiological aspects of irisin remain unknown. Some previous studies even questioned the existence of irisin22, 
although that point was clarified recently by Jedrychowski and coworkers23 who showed that human irisin exists, 
circulates, and is regulated by exercise.
The main aim of this study was to test the hypothesis that metabolic status regulates both central and periph-
eral FNDC5 mRNA expression levels and irisin synthesis and secretion. Most of the published works studied the 
effects of irisin on browning in subcutaneous adipose tissue, but few did so on other fatty deposits16. To elucidate 
the relationship between serum irisin and FNDC5 mRNA expression levels, we evaluated FNDC5 mRNA expres-
sion levels in the hypothalamus, gastrocnemius muscle, brown adipose tissue and visceral (abdominal), epididy-
mal and subcutaneous adipose tissue. We used different models of altered metabolism: rats reared with a high-fat 
diet (HFD) or caloric restriction (CR) for three months, fasting, and treatments with leptin, insulin, metformin, 
alloxan and alloxan plus insulin.
Materials and Methods
Animals. All experiments and animal protocols involved in this study were reviewed and approved by the 
Ethics Committees of the University of A Coruña and CHUAC, in accordance with EU Normative for the use of 
experimental animals. Wistar rats of different ages used in this study were housed in a temperature controlled 
room with a 12 h light, 12 h dark cycle (lights from 08:00 to 20:00 h). To study the expression of profile of FNDC5 
mRNAs we used females to obtain ovaries and placenta samples in the remaining experiments we used males. All 
rats were provided with ad libitum access to water.
Body composition and tissue dissection. Liver and visceral and epididymal WAT were dissected and 
weighed, and somatic indices were calculated as the ratio between tissue and body weights. Rats were killed by 
cervical dislocation and trunk blood was extracted. The hypothalami were dissected and stored at − 80 °C until 
further processing for real-time PCR assays. The hypothalamus was defined by the posterior margin of the optic 
chiasm and the anterior margin of the mammillary bodies to a depth of approximately 2 mm, following previous 
protocols24.
Quantitative real-time PCR. Total RNA was extracted from tissues using TRIzol reagent (Invitrogen). 
RNA quality and concentrations were determined by agarose gel electrophoresis and spectrophotometry in a 
ND-1000 NANODROP 385 spectrophotometer (Thermo-Scientific), respectively. Real-time PCR was performed 
on a Roche LightCycler 480 Real Time PCR Detection System. For mRNA quantification, 1 μ g of total RNA per 
tissue sample was treated with RQ1 RNAse-free DNAse-I (Promega) and retro-transcribed (RT) in a 30 μ l reac-
tion, using M-MLV reverse transcriptase and random primers (Invitrogen). For PCR, we used SYBR Green qPCR 
Master Mix (Roche). The primers used were: HPRT forward 5′ -AGCCGACCGGTTCTGTCAT-3′ ; HPRT reverse 
5′ -GGTCAATAACCTGGTTCATCATCAC-3′ ; FNDC5 forward 5′ -GAGGTGCTGATCATCGTCGT-3′ ; FNDC5 
reverse 5′ -GAGCAAGCACTGAAAGGGTTT-3′ ; SOCS3 forward 5′ -ACCACTACATGCCGCCCCCA-3′ ; SOCS3 
reverse 5′ -TCGGCTCAGTACCAGCGGGA-3′ ; UCP1 forward 5′ -CAATGACCATGTACACCAAGGAA-3′ ; 
UCP1 reverse 5′ -GATCCGAGTCGCAGAAAAGAA-3′ . For data analysis, the input value of the target gene was 
standardized to the HPRT value for each sample. PCR was initiated by one hold of 95 °C for 10 min, followed by 
40 cycles of 15 s at 95 °C, 55 s at 60 °C, and 5 s at 72 °C, followed by one hold of 72 °C for 10 min.
Plasma measurements. Irisin and insulin levels were measured in plasma samples by commercially availa-
ble ELISA kits according to the manufacturer’s specifications (Adipogen and DRG respectively). Intra- and inter- 
assay coefficients of variations for ELISAs were below 8% and 10% (irisin) and 3% and 5% (insulin) respectively.
Experimental design. Tissue distribution and differential expression of the FNDC5 gene in rats. The expres-
sion of profile of FNDC5 mRNAs was explored in a broad panel of tissues from adult (> 75 days-old, n = 3) male 
and female rats. The tissues were removed, quick frozen and stored at − 80 °C until used for RT-PCR expression 
analyses.
Alterations in FNDC5 gene expression and circulating irisin levels in rats reared with different diets: Long-term 
experiments. In order to define the hypothalamic, skeletal muscle and brown and white adipose tissue FNDC5 
mRNA profiles and serum irisin levels and their possible variation with different body weights, % fat mass, insu-
lin sensitivity and other obesity-related factors, 30 male rats were used. At weaning day (postnatal day 21), the 
animals were randomly divided into three groups: (1) control group, with ad libitum access to standard chow diet 
(ND = normal diet) (3.85 kcal/g; 10% kcal % fat; Research Diets, Inc.) (n = 10); (2) diet induced obesity (DIO) 
group, with ad libitum access to HFD diet (4.73 kcal/gm; 45% kcal % fat; Research Diets, Inc.) (n = 10); and (3) 
CR group (n = 10), with standard chow diet but the food was restricted to 65% of the daily amount ingested by 
the control group. To this CR group, a fixed amount of food was provided daily, and the animals ate all the food 
offered. The animals subjected to this feeding regimen had a lower percentage of body fat and increased sensitivity 
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to insulin. The animals were housed under these feeding regimens for three months until they were sacrificed. 
Animals were sacrificed two hours after the beginning of the light phase at 10:00 a.m.
Alterations in FNDC5 gene expression and circulating irisin levels by fasting: Short-term experiments. We evalu-
ated the impact of caloric restriction under a short-term duration. To this end, adult rats (BW: 260 g ± 4, 11 weeks 
of age) were fed with ND and subjected to fasting for 48 hours.
Effects of leptin in FNDC5 gene expression and circulating irisin levels in fed and fasted rats. To monitor changes 
in FNDC5 mRNA expression and circulating irisin in conditions of altered leptin signalling, adult rats (350 g ± 9) 
were fed ad libitum and received two intraperitoneal (IP) injections of leptin (Prospec, 1 mg/kg dissolved in 200 μ l 
of saline) or saline (control group). Injections were applied 24-h and 2-h prior to animal sacrifice. Treatments 
started at 08:00 a.m. and were carried out in the light phase.
In an attempt to establish if leptin regulates hypothalamic and peripheral FNDC5 mRNA expression levels and 
plasma irisin levels in a nutritional-dependent fashion, we fed ad libitum one group of adult rats (189 g ± 9) and 
another group was deprived of food for 48 h. Fed (with normal values of insulin, leptin and glucose) and fasted 
(state associated with low levels of insulin, glucose and leptin) rats received two IP injections of leptin (Prospec, 
1 mg/kg dissolved in 200 μ l of saline) or vehicle. Injections were applied at 24-h and 48-h after the beginning of 
fasting. Treatments started at 08:00 a.m. and were carried out in the light phase. Animals were sacrificed 2-h after 
the 2nd injection (10:00 a.m.).
Effects of insulin and metformin in FNDC5 gene expression and circulating irisin levels. To evaluate the impact 
of insulin and insulin sensitizers in FNDC5 mRNA expression and plasma irisin levels, we treated rats fed with 
ND with insulin or metformin for 2 weeks. To this end, adult rats (290 g ± 2.2) were fed ad libitum. Insulin 
(Novo Nordisk Phama, 1 UI/kg, dissolved in 200 μ l of saline and administrated IP), metformin (Sandoz, 300 mg/kg, 
dissolved in 200 μ l of saline and administrated subcutaneously) and vehicle treatments were carried out in the 
light phase. Animals were sacrificed 2 h after the last injection (day 15).
Effects of irisin in serum insulin and glucose levels in fed rats. To monitor changes in circulating insulin and glu-
cose levels in conditions of altered irisin, adult rats (197 g ± 3.5) were fed ad libitum and received two intraperito-
neal (IP) injections of irisin (Phoenix, 20 μ g/rat dissolved in 200 μ l of saline) or saline (control group). Injections 
were applied 24-h and 2-h prior to animal sacrifice. Treatments started at 09:00 a.m. and were carried out in the 
light phase.
Effects of diabetes on FNDC5 gene expression and circulating irisin levels in fed and fasted rats. In order to assess 
the effect of diabetes on FNDC5 mRNA expression and circulating irisin levels, two new experiments were con-
ducted in which we induced diabetes in adult rats (274 g ± 3.2) by a single injection of alloxan (Sigma-Aldrich, 
130 mg/kg dissolved in 200 μ l of saline and administrated IP). In one of them, six days after alloxan injection a 
group of rats was fasted for 48 h to reduce glucose levels. The animals were sacrificed 8 days after alloxan injection.
In the other experiment, nine days after alloxan injection part of the rats were treated with subcutaneous 
injections of exogenous human NPH insulin to maintain glycemia in these animals as close to the normoglycemia 
as possible. The glucose levels were measured every day at 12:00 h and 20: 00 h with a glucometer and a blood 
drop from the tail vein. The normal dose of NPH insulin was 9.5 U/day but the daily dose of insulin was adjusted 
according to the glycemia of each animal. Two units of insulin were injected at 13:00 h and the 7.5 remaining units 
at 21:00 h. The control group received saline solution. The animals were sacrificed 8 days after insulin treatment.
Statistical analysis. Data were analysed using SigmaStat 3.1 (Systat Software, Inc.) and are presented as the 
means ± SEM. Statistical significance was determined by t-tests (experiments with two groups), one-way ANOVA 
with post hoc Tukey’s tests (experiments with more than two groups and one variable) or two-way ANOVA with 
post hoc Tukey’s tests (experiments with more than two groups and two variables). P < 0.05 was considered signif-
icant. Different letters or symbols above bars indicate statistical significance.
Results
Tissue distribution and differential expression of the FNDC5 gene in rats. As shown in Fig. 1, 
FNDC5 mRNA is prominently expressed in different brain areas and muscle (both cardiac and skeletal). Brown 
adipose tissue, pituitary, placenta, testis and ovary also showed relatively high expression levels with modest 
expression in the depots of white adipose tissue. Other tissues such as lung, kidney, liver, and stomach had very 
low or undetectable FNDC5 mRNA levels.
Alterations in FNDC5 gene expression and circulating irisin levels in rats reared with different 
diets: Long-term experiments. Corporal and some plasmatic parameters of rats reared for three months 
with different diets were published previously25. The % fat mass was very low in animals reared in CR (scarcely a 2%) 
and increased to 9.5% in the control group and 18.8% in animals with HFD (Table 1). The animals subjected to 
CR displayed signs of increased insulin sensitivity because they had the lowest basal glucose and insulin levels. 
In contrast, HFD rats presented signs of insulin resistance and metabolic deregulation, as evidenced by higher 
basal glucose, insulin, and leptin and increased plasma triglyceride concentrations (Table 1)25. To monitor if met-
abolic alterations induced by the different diets influence circulating irisin levels and FNDC5 gene expression, we 
analysed serum irisin values and FNDC5 mRNA expression by real-time RT-PCR. As shown in Fig. 2A, animals 
subjected to CR and HFD displayed diminished serum irisin levels but the differences were not statistically sig-
nificant. No changes were observed in hypothalamic (Fig. 2B) FNDC5 mRNA expression. The expression profiles 
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of FNDC5 in muscle (Fig. 2C) and inguinal subcutaneous WAT (Fig. 2G) were similar to the circulating levels 
of irisin, with lower values in the CR in both tissues and in subcutaneous WAT in animals fed with HFD. Levels 
of FNDC5 and UCP1 (uncoupling protein 1) gene expression in BAT (Fig. 2D,E) increased in proportion to the 
percentage of fat mass and FNDC5 gene expression was enhanced with CR in visceral (Fig. 2F) and epididymal 
(Fig. 2H) WAT.
Alterations in FNDC5 gene expression and circulating irisin levels in fasted rats: short-term 
experiments. Main body parameters and plasma levels of key factors in rats fasted for 48 h are shown in 
Table 2. As expected, BW gain and glucose, insulin, and triglyceride plasma levels diminished with fasting. The 
epididymal-somatic index did not change with the fast, while the percentage of visceral fat and hepatic somatic 
index decreased in fasted rats (Table 2).
The results FNDC5 mRNA expression and circulating irisin levels during fasting are shown in Fig. 3. 
Interestingly, a 48-h fast led to a decrease in serum irisin levels (Fig. 3A) and reduced FNDC5 mRNA levels in 
muscle (Fig. 3C), BAT (Fig. 3D) and in visceral and epididymal white adipose tissue (Fig. 3F,H). Values of FNDC5 
mRNA in subcutaneous WAT did not change (Fig. 3G). UCP1 expression levels in BAT (Fig. 3E) decreased signif-
icantly with fasting, just like did FNDC5 values. In the hypothalamus, the effect of fasting was contrary although 
the difference was not statistically significant (P > 0.05) (Fig. 3B). These results suggest that fasting has different 
effects on central and peripheral FNDC5 gene expression.
Effects of leptin on FNDC5 gene expression and circulating irisin levels. The efficiency of the treat-
ment was corroborated by the increased expression of hypothalamic suppressor of cytokine signalling 3 (SOCS3) 
(Fig. 4B), a primary target of leptin with a negative feedback regulation26. Interestingly, leptin treatment was asso-
ciated with increased hypothalamic FNDC5 expression levels (Fig. 4C) but decreased serum irisin levels (Fig. 4A) 
like muscle (Fig. 4D), BAT (Fig. 4E) and visceral (Fig. 4G), subcutaneous (Fig. 4H) and epididymal (Fig. 4I) 
white adipose tissue FNDC5 gene expression. These results suggest that leptin has different effects on central and 
Figure 1. Expression profile of the FNDC5 gene in different tissues in the adult rat. A panel of tissues from 
adult male and female (ovary and placenta) rats was screened for expression of FNDC5 mRNAs, using real-time 
RT-PCR.
CR ND HFD
Fat mass (%) 2.1 ± 0.6 a 9.5 ± 0.5 b 18.8 ± 0.9 c
Lean mass (%) 80.3 ± 0.7 a 73.1 ± 0.7 b 66.2 ± 0.8 c
Body weight gain (g) 173.2 ± 4.8 a 306.8 ± 9.0 b 362.0 ± 7.3 c
Glucose (mg/dl) 72.0 ± 1.4 a 78.44 ± 1.0 b 139.3 ± 4.0 c
Insulin (ng/ml) 1.01 ± 0.1 a 3.2 ± 0.3 b 4.1 ± 0.3 c
Leptin (ng/ml) 3.3 ± 0.6 a 8.5 ± 1.0 b 15.7 ± 0.8 c
Tryglicerides (mg/dl) 64.1 ± 3.9 a 120.8 ± 6.2 b 148.1 ± 8.3 c
Table 1.  Effect of caloric restriction and high fat diet during 3 months on % fat mass, % lean mass, 
body weight gain, and plasma glucose, insulin, leptin and triglycerides levels. Values are expressed as 
mean ± SEM. Different letters indicate statistical differences (One-way ANOVA with post hoc Tukey test, a value 
of P < 0.05 was considered statistically significant). CR: caloric restriction (n = 10), ND: normal diet (n = 10) 
and HFD: high fat diet (n = 10). The animals were reared in these diets during three months after weaning.
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peripheral FNDC5 gene expression, which is similar to the effects of fasting. Unlike FNDC5 gene expression, no 
changes were observed in BAT UCP1 mRNA expression levels after treatment with leptin (Fig. 4F).
In order to corroborate the previous results and to assess if leptin regulates hypothalamic and peripheral 
FNDC5 mRNA expression levels and plasma irisin levels in a nutritional-dependent fashion we repeated the last 
experiment but in fed and fasted rats. The results are showed in Fig. 5.
Overall, there was a significant (P < 0.001 fed vs. fast and P = 0.031 vehicle vs. leptin, two-way ANOVA) effect 
of fasting and leptin treatment on plasma irisin levels but no significant (P > 0.05, two-way ANOVA) effect of lep-
tin treatment × status nutritional interaction, although the comparisons for leptin treatment within fed animals 
had a P = 0.055, similar to the diminished irisin levels in fasting animals in the previous experiment (Fig. 5A). 
In the hypothalamus, SOCS3 gene expression increased in all animals treated with leptin and diminished with 
Figure 2. Effect of the HFD and CR for three months on plasma irisin (A) levels, FNDC5 expression levels 
in the hypothalamus (B), muscle (C), BAT (D) and visceral (F), subcutaneous (G) and epididymal (H) white 
adipose tissue of adult male rats and UCP1 expression levels in BAT (E). Values are expressed in μ g/ml for 
circulating irisin and arbitrary units for FNDC5 and UCP1 gene expression, as the mean ± SEM, where 
ND = 100%. Different letters above the bars indicate statistical differences (One-way ANOVA with post hoc 
Tukey’s test, a value of P < 0.05 was considered statistically significant). CR: caloric restriction (n = 10), ND: 
normal diet (n = 10) and HFD: high fat diet (n = 10). The animals were reared on these diets for three months 
after weaning.
Body weight 
gain (g)
Glucose 
(mg/dl)
Insulin 
(ng/ml)
Triglycerides 
(mg/dl)
Somatic index. 
Liver (g/100 g BW)
Somatic index. 
Epididymal (g/100 g BW)
Somatic index. 
Visceral (g/100 g BW)
Fed 41.2 ± 2.5 120 ± 1.5 2.3 ± 0.3 162 ± 13 3.7 ± 0.1 0.96 ± 0.05 0.68 ± 0.04
Fast 11.6 ± 4.4* 91 ± 1.1* 0.44 ± 0.07* 68 ± 4.7* 2.6 ± 0.08* 0.88 ± 0.05 0.49 ± 0.05* 
Table 2.  Effect of fasting during 48-h on body weight gain, plasma glucose, insulin and triglycerides levels 
and somatic indices. Values are expressed as mean ± SEM. * P < 0.05 vs. fed, t-test, n = 6. Somatic index was 
calculated as the ratio between tissues weight and body weight and was expressed as g/100 g body weight (BW).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:29898 | DOI: 10.1038/srep29898
fasting (Fig. 5B). In concordance with the previous results, FNDC5 mRNA expression levels diminished in mus-
cle tissue of animals treated with leptin but this effect disappeared with fasting (Fig. 5D). Similar results were 
obtained for the hypothalamus, where FNDC5 mRNA expression levels increased in fed animals treated with 
leptin; however, this effect was not present in fasted animals (Fig. 5C).
Effects of insulin and metformin on FNDC5 gene expression and circulating irisin levels. As expected, insulin 
and metformin injections diminished glucose levels demonstrating their efficacy (Table 3). Insulin and met-
formin treatments provoked a lower body weight gain with respect to controls; however, epididymal and vis-
ceral WAT mass were unchanged in insulin treated rats. With metformin, epididymal somatic index diminished 
with respect to controls and insulin treated rats. The hepatosomatic index and plasma triglyceride levels were 
reduced in insulin-treated rats (Table 3). Plasma irisin levels diminished in animals treated with insulin (Fig. 6A). 
Hypothalamic FNDC5 mRNA expression levels increased with insulin and metformin treatments (Fig. 6B). 
Muscle FNDC5 mRNA expression levels diminished in rats treated with insulin and metformin with respect to 
their controls, although with metformin the differences were not statistically significant (Fig. 6C). WAT FNDC5 
gene expression increased with metformin (Fig. 6D,E), however in epididymal WAT (Fig. 6D) the differences 
were again not significant.
Effects of irisin in serum insulin and glucose levels in fed rats. Exogenous irisin treatment caused a 
physiologic increase in circulating irisin levels (Fig. 6F). In turn, irisin caused an increase in the amount of circu-
lating insulin (Fig. 6G) without altering blood glucose levels (Fig. 6H).
Effects of diabetes on FNDC5 gene expression and circulating irisin levels. As expected, blood 
glucose levels in both fed and fasted rats treated with alloxan were higher compared with their controls (Fig. 7A). 
When fed rats showed blood glucose levels higher than 260 mg/dl were classified as diabetic. Insulin levels 
Figure 3. Effect of 48 h of fasting on plasma irisin (A) levels, FNDC5 expression levels in the hypothalamus (B), 
muscle (C), BAT (D) and visceral (F), subcutaneous (G) and epididymal (H) white adipose tissue and UCP1 
expression levels in BAT (E) of adult male rats. Values are expressed in μ g/ml for circulating irisin and arbitrary 
units for FNDC5 and UCP1 gene expression, as the mean ± SEM, where fed = 100%. N = 6. Different symbols 
above the bars indicate statistical differences (t-test, a value of P < 0.05 was considered statistically significant).  
* P < 005 vs. fed.
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diminished significantly in animals treated with alloxan and with fasting (Fig. 7B). Alloxan treatment diminished 
the percentage of visceral and epididymal WAT considerably both in fed and fasted rats (data not shown). Plasma 
irisin levels diminished with alloxan in fed and fasted animals with respect to their controls (Fig. 7C). Fasting 
was also associated with reduced circulating levels of irisin (as we observed in experiment 3), but only in control 
animals (Fig. 7C). The FNDC5 gene showed a similar expression profile in muscle (Fig. 7E). However, epididy-
mal WAT FNDC5 mRNA expression levels increased with alloxan treatment in fed and fasted rats (Fig. 7F). No 
differences were observed in hypothalamic FNDC5 gene expression (Fig. 7D). Again, muscle FNDC5 mRNA 
expression levels diminished with fasting but only in control rats (Fig. 7E). Diabetes also diminished FNDC5 
gene expression but this effect was dependent of nutritional status. Independently of feeding, WAT FNDC5 gene 
expression increased substantially with alloxan treatment (Fig. 7F).
In the next experiment, we tested if parameters altered by alloxan-induced diabetes can be reversed by insulin 
therapy. As in the previous experiment, the alloxan treatment induced a robust increase in blood glucose levels 
nine days after alloxan injection (Fig. 8A). Glucose levels dropped below 200 mg/dl 48 h after beginning insulin 
treatment, and after 5 days normoglycemic levels were maintained until the animals were sacrificed (Fig. 8A). No 
changes were observed in plasma irisin levels of animals treated with alloxan with respect to the control group; 
however they showed lower levels than the rats subjected to insulin therapy (Fig. 8B). Hypothalamic SOCS3 
(Fig. 8C) and FNDC5 (Fig. 8D) mRNA expressions decreased in diabetic rats. But unlike FNDC5 gene expression, 
SOCS3 mRNA expression levels were reversed by insulin treatment. FNDC5 mRNA expression was reduced in 
muscle (Fig. 8E) and BAT (Fig. 8F) in diabetic rats. UCP1 gene expression in BAT (Fig. 8G) showed exactly the 
same pattern that FNDC5 mRNA expression levels, reinforcing the hypothesis that UCP1 and FNDC5 are related. 
In muscle, the values were recovered by insulin treatment. In all WAT depots studied, FNDC5 gene expression 
enhanced with diabetes, and these values decreased significantly (even over control values) after insulin treatment 
(Fig. 8H–J).
Figure 4. Effect of 2-day IP leptin treatment in fed animals on plasma irisin (A) levels, SOCS3 gene expression 
(B), FNDC5 expression levels in the hypothalamus (C), muscle (D), BAT (E) and visceral (G), subcutaneous 
(H) and epididymal (I) white adipose tissue of adult male rats and UCP1 expression levels in BAT (F). Values 
are expressed in μ g/ml for circulating irisin and arbitrary units for FNDC5 and SOCS3 gene expression, as the 
mean ± SEM, where control = 100%. n = 6–7. * , * * * P < 0.05 and 0.01 respectively vs. control (rats injected with 
saline) (t-test).
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Discussion
Initially irisin was described as a myokine that induces white fat “browning” in vivo and in vitro12, and later as 
an adipokine16. Since its discovery there have been numerous published studies about its regulation and func-
tion. Böstrom et al. proposed that FNDC5 was cleaved producing the soluble protein irisin that increases total 
body energy expenditure and resistance to obesity-linked insulin-resistance, and that this effect was a result of 
browning produced by irisin in adipose tissue12. Both in humans and rodents correlated brown fat tissue forma-
tion with anti-obesity effects, suggesting a central role of beige adipocyte thermogenesis in whole-body energy 
metabolism27–29. However, controversy has emerged regarding the association between irisin and obesity or met-
abolic disorders. Some studies have suggested that irisin ameliorates obesity, glucose disorders and insulin resist-
ance14,30,31 and that circulating irisin is negatively associated with BMI and percentage of fat mass14,32; however, 
other studies have found that irisin is positively correlated with these parameters33,34 while others have revealed 
no correlation between irisin and BMI35–37.
To elucidate the relationship between serum irisin levels and FNDC5 gene expression in different tissues, we 
evaluated blood irisin levels and FNDC5 mRNA expression levels in the hypothalamus, gastrocnemius muscle, 
brown adipose tissue and different depots of WAT [visceral (abdominal), epididymal and subcutaneous] in dif-
ferent models of altered metabolism and moreover we studied the effects of exogenous irisin on insulin levels.
To begin, we studied the distribution of FNDC5 mRNA expression in different rat tissues. As previously 
reported, FNDC5 mRNA was expressed in high levels in muscles20,34 and also in all brain regions analysed18,38 
suggesting a role for FNDC5/irisin in the brain. This theory is supported by different reports of FNDC5/irisin 
function in different brain processes. Endurance exercise enhances FNDC5 gene expression in the hippocampus 
of mice which in turn stimulates BDNF gene expression and forces expression of FNDC5 in primary cortical 
Figure 5. Effect of 2-day IP leptin treatment in fed and fasted animals on plasma irisin levels (A), SOCS3 
gene expression (B) and FNDC5 expression levels in the hypothalamus (C), muscle (D), and epididymal (E) 
white adipose tissue of adult male rats. Values are expressed in μ g/ml for circulating irisin and arbitrary units 
for FNDC5 and SOCS3 gene expression, as the mean ± SEM, where fed animals treated with saline were the 
controls = 100%. n = 6–7. Different symbols above bars indicate statistical differences (Two-way ANOVA with 
post hoc Tukey’s test, a value of P < 0.05 was considered statistically significant). * P < 005 vs. fed; #P < 0.05 vs. 
saline.
Body weight 
gain (g)
Glucose  
(mg/dl)
Triglycerides 
(mg/dl)
Somatic index. 
Liver (g/100 g BW)
Somatic index. 
Epididymal (g/100 g BW)
Somatic index. 
Visceral (g/100 g BW)
Control 50.0 ± 1.8 a 131.8 ± 4.7 a 116.6 ± 6.5 a 3.5 ± 0.1 a 1.57 ± 0.09 a 1.0 ± 0.06
Metformin 20.7 ± 7.4 b 91.0 ± 11.5 b 97.5 ± 10.5 a,b 3.3 ± 0.2 a,b 1.20 ± 0.03 b 0.9 ± 0.06
Insulin 41.4 ± 1.6 c 70.5 ± 10.5 b 69.76 ± 4.84 b 3.0 ± 0.1 b 1.63 ± 0.12 a 1.0 ± 0.04
Table 3.  Effect of a 14-day IP saline and insulin and subcutaneous metformin treatment on body weight 
gain, and plasma glucose and triglycerides levels and somatic index. Values are expressed as mean   SEM. 
Different letters indicate statistical differences by treatment (One-way ANOVA with post hoc Tukey test, a 
value of P < 0.05 was considered statistically significant). N = 6 (metformin treatment) or 8 (saline and insulin 
treatments). Somatic index was calculated as the ratio between tissues weight and body weight and was 
expressed as g/100 g body weight (BW).
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neurons increasing cell survival20. In humans, irisin was detected in cerebrospinal fluid and hypothalamic sec-
tions, especially paraventricular neurons, colocalising with neuropeptide Y21. We also reported high levels 
of FNDC5 mRNA expression in BAT, which could be due to the prominent role of BAT in the release of heat 
through the action of UCP1 and in the control of glucose and lipid metabolism39 since cold exposure increases 
circulating irisin levels40 in addition to irisin driving brown-fat-like development of white fat and thermogene-
sis stimulating UCP1 expression12. In this work, we demonstrated that the FNDC5 and UCP1 gene expression 
patterns are identical in BAT during chronic caloric restriction, fasting, feeding with HFD and treatments with 
alloxan or alloxan plus insulin. These results are supported by other studies in rodents demonstrating that HFD 
increases brown adipose tissue UCP1 mRNA and protein content41 and that fasting diminishes UCP1 gene and 
protein expression42. We observed that alloxan treatment clearly reduced FNDC5 expression in BAT, which 
could be explained by a reduced thermogenic capacity of BAT as noted in animal studies with chronic insu-
lin deficiency43,44. Furthermore, mice with type 1 diabetes mellitus showed a reversion of glucose homeostasis 
to normalcy increasing BAT quantity by transplants45. After acute leptin treatment in fed rats, we observed no 
differences in BAT UCP1 mRNA, as is consistent with previous reports42,46; however, FNDC5 mRNA expression 
was reduced in these conditions. Sivitz et al. observed that leptin effects on UCP1 mRNA and protein levels may 
be discordant42, therefore it cannot be ruled out that our discrepancies are due to the tendency for UCP1 mRNA 
and protein expression levels after leptin treatment to be different or even that this also occurs with FNDC5. The 
relatively high expression of FNDC5 in the reproductive neuroendocrine axis (hypothalamus, pit, ovary, testis and 
Figure 6. Effect of a 14-day IP saline and insulin and subcutaneous metformin treatment on plasma irisin 
levels (A) and FNDC5 expression levels in the hypothalamus (B), muscle (C) and epididymal (D) and visceral 
(E) WAT of adult male rats and effect of 2-day IP irisin treatment in fed animals on plasma irisin (F), insulin 
(G) and glucose levels (H). Different letters above the bars indicate statistical differences (One-way ANOVA 
with post hoc Tukey’s test, a value of P < 0.05 was considered statistically significant). * * * P < 0.05 and 0.01 
respectively vs. control (rats injected with saline) (t-test). Values are expressed as the mean ± SEM where 
animals treated with saline. N = 6 (metformin treatment), 8 (saline and insulin treatments) and 7 (irisin 
treatment). Values are expressed in mg/dl for plasma glucose levels, ng/ml for plasma insulin levels and μ g/ml  
for circulating irisin levels. Arbitrary units were used for FNDC5 gene expression where rats injected with 
saline = 100%.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:29898 | DOI: 10.1038/srep29898
placenta) suggests an effect of irisin on reproductive function. However, additional studies are required to clarify 
whether such a relationship exists.
It must be borne in mind that different WAT depots may differ in physiological function. Excess accumulation 
of visceral adipose in the abdominal cavity is associated with metabolic syndrome, diabetes, cardiovascular dis-
ease and mortality47. However, in rodents, subcutaneous WAT, appears to be relatively benign and transplantation 
of subcutaneous adipose tissue from normal48 or exercise-trained donor49 to visceral cavity can improve glucose 
metabolism and insulin sensitivity. Irisin may promote maintenance of “healthy” subcutaneous adipose because 
FNDC5 is induced by exercise in this depot and increases brown/beige fat cells12. Although WAT FNDC5 gene 
expression may represent only a small fraction of that expressed in muscle, brain, or even brown adipose tissue, 
Moreno-Navarrete et al. suggested that it is the adipose tissue (studies realized with visceral and subcutaneous 
WAT) and not the skeletal muscle expression that correlates with levels of circulating irisin in humans14. In sup-
port, Yang et al. demonstrated that FNDC5 protein expression in adipose tissue, not skeletal muscle, contributed 
to the change of circulating irisin in HFD-induced obese mice50; but, Yang et al. only analysed subcutaneous 
abdominal adipose tissue. However, the existence of diverse fat depot states in rats offers the possibility of dif-
ferential contributions from these depots to circulating irisin levels. To explore this, we analysed FNDC5 gene 
expression in epididymal, visceral (abdominal) and subcutaneous WAT and BAT during different states of meta-
bolic distress. We observed that the alterations in blood irisin levels resulting from changes in the feeding depend 
on the duration and nature of the changes. In long-term experiments, neither caloric restriction nor high fat diet 
cause changes in the circulating irisin levels, however with 48 hours of fasting, blood irisin levels drop along with 
the decline observed in FNDC5 mRNA expression levels in muscle, BAT and visceral and epididymal adipose tis-
sue. However, changes were not observed in subcutaneous fat, suggesting that the changes produced in circulating 
irisin levels with short-term restriction caloric are not related to FNDC5 gene expression levels in subcutaneous 
fat, but could be related to variations in muscle, BAT or other white fat depots such as visceral or epididymal. 
During long-term experiments, BAT FNDC5 mRNA expression levels increased proportionally to the percent-
age of fat mass. In WAT after three months with CR, FNDC5 mRNA expression levels increased in epididymal 
and visceral adipose tissue but diminished with CR and HFD in subcutaneous fat, demonstrating differences in 
FNDC5 expression depending on the adipose tissue depot. We suggest that the increase observed in epididymal 
and visceral WAT FNDC5 expression, or at least partially, during CR occurs in an attempt to compensate for the 
decrease that occurs in the mass of those deposits, which were more affected by CR than the subcutaneous WAT51. 
This hypothesis is reinforced by the increase in FNDC5 mRNA expression levels in all WAT depots in diabetic 
rats, concomitant with a significant decrease in their fat mass, which even disappears (data not shown). We sug-
gest that circulating irisin levels are a reflection of the combination of irisin released from various fat depots and 
from muscle, and that when the amount of WAT decreases substantially, FNDC5 levels in these depots increase to 
attempt to compensate for the tissue loss, which may explain some of the observed discrepancies between insulin 
levels and FNDC5/irisin, such as metformin treatment or long-term caloric restriction.
Figure 7. Effect diabetes induced by a single injection of alloxan in fed and fasted (48 h) animals on plasma 
glucose (A) insulin (B) and irisin (C) levels and FNDC5 gene expression levels in the hypothalamus (D), 
muscle (E) and epididymal (F) WAT of adult male rats. * P < 0.05 vs. fed animals. #P < 0.05 vs. saline. (Two-
way ANOVA with post hoc Tukey’s test, a value of P < 0.05 was considered statistically significant). Values are 
expressed in mg/dl for plasma glucose levels, ng/ml for plasma insulin levels and μ g/ml for circulating irisin 
levels. Arbitrary units were used for FNDC5 gene expression, as the mean ± SEM, where rats fed and injected 
with saline = 100%. N = 8 (saline treatment) or 10 (alloxan treatment).
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Hypothalamic FNDC5 expression did not change with any of the tested diets suggesting that its regulation 
does not depend on alimentation/nutrition. In this work, we observed that an acute leptin treatment increased 
hypothalamic FNDC5 transcript levels and diminished their levels in gastrocnemius, BAT and visceral adipose 
tissue correlating nicely with the observed decline in circulating irisin levels. However, these differences disap-
peared in rats that had fasted for 48 h suggesting that peripheral leptin regulates hypothalamic and peripheral 
FNDC5 gene expression in a nutritional-dependent fashion. In a previous work, Rodriguez et al. observed that 
leptin administration was associated with increased gastrocnemius FNDC5 transcript levels, a slight increase in 
circulating irisin in mice and downregulated FNDC5 expression in murine differentiated subcutaneous adipo-
cytes52. Additional studies are required to identify the source of the discrepancies between different experiments, 
including the experimental design and animal model.
Numerous studies have reported a positive association of muscle FNDC5/irisin with insulin resistance, spec-
ulating on the negative desensitizing effects of irisin on insulin action16,34,53. However, the results of our study 
also support a relationship between insulin production and the levels of circulating irisin. Acute treatments with 
exogenous irisin enhanced circulating insulin levels displaying a relationship between irisin and insulin produc-
tion. Moreover, situations with low levels of insulin including fasting and CR and treatments with leptin, alloxan, 
metformin or insulin (which decreases endogenous insulin production) are associated with reduced FNDC5 gene 
expression levels in muscle but also reduced circulating irisin levels in most cases. These results are consistent 
with a recent study demonstrating that serum irisin concentrations were lower in type 2 diabetes mellitus patients 
and increased after continuous subcutaneous insulin54.
Two recent works in mouse showed that metformin promotes FNDC5 gene expression and irisin release from 
skeletal muscle55,56. The differences with respect to this work could be due to the species, mice vs. rats and/or also 
to the effects of the metformin in the weight and body composition. In our case, the treatment with metformin 
resulted in a sharp decrease in both body weight and fat mass gain, but not in the mentioned works where no var-
iations were observed on body weight of wild-type mice treated with metformin. Supporting this theory Li et al. 
found that after 6 months of metformin treatment, there was a significant decrease in % fat mass, body weight and 
circulating irisin in polycystic ovary syndrome women57. However, to clarify this point further studies are needed, 
where the body weight gain do not change between controls and rats treated with metformin.
Figure 8. Effect of treatment of diabetic rats using 9.5 IU/day of NPH insulin for 8 days on plasma glucose 
levels (A) and effect after 8-day treatments of diabetics with insulin on plasma irisin (B) levels and SOCS3 
(C), FNDC5 expression levels in the hypothalamus (D), and FNDC5 expression levels in muscle (E), BAT 
(F) and visceral (H), subcutaneous (I) and epididymal (J) white adipose tissue of adult male rats and UCP1 
expression levels in BAT (G). * P < 0.05 vs. diabetics rats injected with saline. Different letters above the bars 
indicate statistical differences (One-way ANOVA with post hoc Tukey’s test, a value of P < 0.05 was considered 
statistically significant). Values are expressed in mg/dl for plasma glucose levels and μ g/ml for circulating irisin 
levels. Arbitrary units were used for FNDC5 and SOCS3 gene expression, as the mean ± SEM, where normal rats 
injected with saline = 100%. N = 8.
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Doubts have been raised about circulating irisin, and there are limitations of the irisin assay22,58. We cannot 
rule out that the ELISA assays used in this study detected false signals from cross-reacting proteins. However, 
Jedrychowski et al. using tandem mass spectrometry have unequivocally shown that human irisin exists, circu-
lates, and is regulated by exercise23. Moreover, they used immunoblotting of irisin plasma samples with a poly-
clonal antibody from the same commercial source as that used in the ELISA assays in this work and detected a 
band at ≈ 12 kDa, the predicted size of the irisin polypeptide23, suggesting that this antibody works efficiently. A 
strong point in our work is that several of the experiments, fasting and leptin and alloxan treatments are repeated 
and the results are replicable for FNDC5 gene expression and serum irisin levels with rare exceptions in alloxan 
experiments that can be explained by the variable duration between the two treatments of alloxan.
In conclusion, FNDC5 mRNA was expressed in high levels in muscles, brain and in the reproductive neuroen-
docrine axis. We demonstrated for the first time that there are differences in FNDC5 expression depending on 
the WAT depot and when the amount of one of these depots decreases considerably, FNDC5 mRNA expression 
increases, probably as a compensatory effect. Serum irisin levels diminish after a 48-h fast and with leptin, insulin 
and alloxan treatments, but no changes were observed during long-term experiments with different diets. We 
suggested that the combination of different depots of adipose tissue and skeletal muscle expression correlates with 
circulating irisin levels. On the other hand, hypothalamic FNDC5 expression did not change for any of the tested 
diets suggesting that their regulation is not dependent on alimentation but was increased with leptin, insulin and 
metformin treatments. These results suggest that the regulation of central and peripheral FNDC5/irisin expres-
sion are different and have different functions. However, additional experiments are required to characterize such 
functions.
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